Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7205-7216

  Parikh, Falguni ^a   Duluc, Dorothée ^b   Imai, Naoko ^a   Clark, Amelia ^a   Misiukiewicz, Krzys ^a   Bonomi, Marcello ^a   Gupta, Vishal ^a   Patsias, Alexis ^a   Parides, Michael ^a   Demicco, Elizabeth G ^a   Zhang, David Y ^a   Kim Schulze, Seunghee ^a   Kao, Johnny ^c   Gnjatic, Sacha ^a   Oh, Sangkon ^b   Posner, Marshall R ^a   Sikora, Andrew G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Baylor Institute for Immunology   (United States)

^c Good Samaritan Hospital Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CABAZITAXEL; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TAXANE DERIVATIVE; PDCD1 PROTEIN, HUMAN; PROTEIN E7;

ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS RELATED OROPHARYNGEAL CANCER; IMMUNE DEFICIENCY; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR ESCAPE; WART VIRUS; BIOSYNTHESIS; CANCER STAGING; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PATHOLOGY;

CD8-POSITIVE T-LYMPHOCYTES; CHEMORADIOTHERAPY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; INDUCTION CHEMOTHERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84918532590     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1913     Document Type: Article

References (47)

1. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-6.
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
3. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
4. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22:1071-7.
5. Münger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217.
6. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-9.
7. Frumento G, Piazza T, Di Carlo E, Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006;6:233-7.
8. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79.
9. Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol 2008;35:221-8.
10. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associatedmyeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
11. Wu X, Feng Q-M, Wang Y, Shi J, Ge H-L, Di W. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother 2010;59:279-91.
12. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
13. + T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15:6341-7.
14. Verastegui EL, Morales RB, Barrera-Franco JL, Poitevin AC, Hadden J. Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol 2003;3:1093-104.
15. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immunedefect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol Head Neck Surg 1998;119:412-7.
16. Gray WC, Chretien PB, Suter CM, Revie DR, Tomazic VT, Blanchard CL, et al. Effects of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngol Head Neck Surg 1985;93:650-60.
17. Wara WM, Ammann AJ, Wara DW. Effect of thymosin and irradiation on immune modulation in head and neck and esophageal cancer patients. Cancer Treat Rep 1978;62:1775-8.
18. Olkowski ZL, McLaren JR, Skeen MJ. Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immuno-competence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy. Cancer Treat Rep 1978;62:1651-61.
19. Stefano S, Kerman R, Abbate J. Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy. Am J Roentgenol 1976;126:880-6.
20. Campian JL, Sarai G, Ye X, Marur S, Grossman SA. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 2014;36:1747-53.
21. Tabachnyk M, Distel LVR, Büttner M, Grabenbauer GG, Nkenke E, Fietkau R, et al. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell pro file in head and neck cancer. Oral Oncol 2012;48:594-601.
22. Vu HL, Sikora AG, Fu S, Kao J. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 2010;288:149-55.
23. Vermeer DW, Spanos WC, Vermeer PD, Bruns AM, Lee KM, Lee JH. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer 2013;133:120-9.
24. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1137-46.
25. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012;2:95.
26. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013;85:293-5.
27. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012;72:3967-76.
28. Delgado FG, Martínez E, Céspedes MA, Bravo MM, Navas MC, Cómbita Rojas AL. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology 2009;126:523-34.
29. Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, et al. Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 2004;100:1418-28.
30. Al-Taei S, Banner R, Powell N, Evans M, Palaniappan N, Tabi Z, et al. Decreased HPV-speci fi c T cell responses and accumulation of immunosuppressive in fl uences in oropharyngeal cancer patients following radical therapy. Cancer Immunol Immunother 2013;62:1821-30.
31. Qinfeng S, Depu W, Xiaofeng Y, Shah W, Hongwei C, Yili W. In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat Res 2013;179:584-9.
32. Battaglia A, Buzzonetti A, Martinelli E, Fanelli M, Petrillo M, Ferrandina G, et al. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010;76:1546-53.
33. Tong CCL, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 2012;54:266-74.
34. Saavedra MM, Henríquez-Hernández LA, Lara PC, Pinar B, Rodríguez-Gallego C, Lloret M. Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients. J Radiat Res 2010;51:603-7.
35. Ukpo OC, Thorstad WL, Lewis JS. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013;7:113-21.
36. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-38.
37. Jie H-B, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-35.
38. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012:656340.
39. Lesterhuis WJ, Punt CJA, Hato SV, Eleveld-Trancikova D, Jansen BJH, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100-8.
40. Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009;35:741-9.
41. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco-Targets Ther 2014;7:567-73.
42. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53.
43. Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM, et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res 2012;18:1925-35.
44. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012;72:3163-74.
45. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.
46. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013;190:5874-81.
47. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343-9.